139 related articles for article (PubMed ID: 37584830)
1. Lymph node ratio as a tool to stratify patients with N1b papillary thyroid cancer.
Luo Z; Hei H; Qin J; Zheng C; Gong W; Zhou B
Langenbecks Arch Surg; 2023 Aug; 408(1):315. PubMed ID: 37584830
[TBL] [Abstract][Full Text] [Related]
2. Optimal value of lymph node ratio and metastatic lymph node size to predict risk of recurrence in pediatric thyroid cancer with lateral neck metastasis.
Back K; Kim TH; Lee J; Kim JS; Choe JH; Oh YL; Cho A; Kim JH
J Pediatr Surg; 2023 Mar; 58(3):568-573. PubMed ID: 35973863
[TBL] [Abstract][Full Text] [Related]
3. Lymph node ratio predicts recurrence in pediatric papillary thyroid cancer.
Rubinstein JC; Dinauer C; Herrick-Reynolds K; Morotti R; Callender GG; Christison-Lagay ER
J Pediatr Surg; 2019 Jan; 54(1):129-132. PubMed ID: 30361076
[TBL] [Abstract][Full Text] [Related]
4. Impact of lymph node ratio on survival in papillary thyroid cancer.
Schneider DF; Chen H; Sippel RS
Ann Surg Oncol; 2013 Jun; 20(6):1906-11. PubMed ID: 23263904
[TBL] [Abstract][Full Text] [Related]
5. Restratification of survival prognosis of N1b papillary thyroid cancer by lateral lymph node ratio and largest lymph node size.
Kim HI; Kim TH; Choe JH; Kim JH; Kim JS; Oh YL; Hahn SY; Shin JH; Jang HW; Kim YN; Kim H; Ahn HS; Kim K; Kim SW; Chung JH
Cancer Med; 2017 Oct; 6(10):2244-2251. PubMed ID: 28857489
[TBL] [Abstract][Full Text] [Related]
6. Lymph node ratio in lateral neck is an independent risk factor for recurrence-free survival in papillary thyroid cancer patients with positive lymph nodes.
Luo Z; Hei H; Qin J; Zheng C; Gong W
Endocrine; 2022 Dec; 78(3):484-490. PubMed ID: 36018538
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for level V metastasis in patients with N1b papillary thyroid cancer.
Kang JG; Choi JE; Kang SH
World J Surg Oncol; 2022 Sep; 20(1):327. PubMed ID: 36180912
[TBL] [Abstract][Full Text] [Related]
8. Analysis of factors associated with the prognosis of papillary thyroid cancer and the construction of a survival model.
Guo P; Wang X; Xia L; Shawureding N; Hu Z
Cancer Med; 2023 Apr; 12(7):7868-7876. PubMed ID: 36560883
[TBL] [Abstract][Full Text] [Related]
9. Assessing the role of central lymph node ratio in predicting recurrence in N1a low-to-intermediate risk papillary thyroid carcinoma.
Ma T; Cui J; Shi P; Liang M; Song W; Zhang X; Wang L; Shi Y
Front Endocrinol (Lausanne); 2023; 14():1158826. PubMed ID: 37790606
[TBL] [Abstract][Full Text] [Related]
10. How Many Nodes to Take? Lymph Node Ratio Below 1/3 Reduces Papillary Thyroid Cancer Nodal Recurrence.
Weitzman RE; Justicz NS; Kamani D; Kyriazidis N; Chen MH; Randolph GW
Laryngoscope; 2022 Sep; 132(9):1883-1887. PubMed ID: 35229306
[TBL] [Abstract][Full Text] [Related]
11. Optimal Cut-Off Values of Lymph Node Ratio Predicting Recurrence in Papillary Thyroid Cancer.
Lee SG; Ho J; Choi JB; Kim TH; Kim MJ; Ban EJ; Lee CR; Kang SW; Jeong JJ; Nam KH; Jung SG; Jo YS; Lee J; Chung WY
Medicine (Baltimore); 2016 Feb; 95(5):e2692. PubMed ID: 26844509
[TBL] [Abstract][Full Text] [Related]
12. Prognostic implications of lymph node yield and lymph node ratio in papillary thyroid carcinoma.
Vas Nunes JH; Clark JR; Gao K; Chua E; Campbell P; Niles N; Gargya A; Elliott MS
Thyroid; 2013 Jul; 23(7):811-6. PubMed ID: 23373961
[TBL] [Abstract][Full Text] [Related]
13. Lymph node ratio predicts recurrence in papillary thyroid cancer.
Schneider DF; Mazeh H; Chen H; Sippel RS
Oncologist; 2013; 18(2):157-62. PubMed ID: 23345543
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of extranodal extension of regional lymph node metastasis in papillary thyroid cancer.
Wu MH; Shen WT; Gosnell J; Duh QY
Head Neck; 2015 Sep; 37(9):1336-43. PubMed ID: 24821456
[TBL] [Abstract][Full Text] [Related]
15. Level V Metastasis, a Novel Predicative Factor for Recurrence in N1b Papillary Thyroid Carcinoma.
Wu Y; Li J; Wu X; Dai L
Curr Pharm Des; 2018; 24(5):559-563. PubMed ID: 28990528
[TBL] [Abstract][Full Text] [Related]
16. Pre-ablation stimulated thyroglobulin is a better predictor of recurrence in pathological N1a papillary thyroid carcinoma than the lymph node ratio.
Chang YW; Kim HS; Jung SP; Kim HY; Lee JB; Bae JW; Son GS
Int J Clin Oncol; 2016 Oct; 21(5):862-868. PubMed ID: 26837274
[TBL] [Abstract][Full Text] [Related]
17. Lymph node ratio (LNR) as a complementary staging system to TNM staging in salivary gland cancer.
Lei BW; Hu JQ; Yu PC; Wang YL; Wei WJ; Zhu J; Shi X; Qu N; Lu ZW; Ji QH
Eur Arch Otorhinolaryngol; 2019 Dec; 276(12):3425-3434. PubMed ID: 31511971
[TBL] [Abstract][Full Text] [Related]
18. Modification of the eight-edition tumor-node-metastasis staging system with N1b for papillary thyroid carcinoma: A multi-institutional cohort study.
Kim M; Kim HK; Kim HI; Kim EH; Jeon MJ; Yi HS; Kim ES; Kim H; Kim TH; Kim BH; Kim TY; Kang HC; Kim WB; Chung JH; Shong YK; Kim SW; Kim WG
Oral Oncol; 2018 Nov; 86():48-52. PubMed ID: 30409319
[TBL] [Abstract][Full Text] [Related]
19. Thyroglobulin expression, Ki-67 index, and lymph node ratio in the prognostic assessment of papillary thyroid cancer.
Lindfors H; Karlsen M; Karlton E; Zedenius J; Larsson C; Ihre Lundgren C; Juhlin CC; Shabo I
Sci Rep; 2023 Jan; 13(1):1070. PubMed ID: 36658256
[TBL] [Abstract][Full Text] [Related]
20. The Clinical Significance of Lymph Node Ratio and Ki-67 Expression in Papillary Thyroid Cancer.
Lindfors H; Ihre Lundgren C; Zedenius J; Juhlin CC; Shabo I
World J Surg; 2021 Jul; 45(7):2155-2164. PubMed ID: 33825961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
